骨科指南

订阅

MedSci主页 / 所有栏目 / 骨科指南

2023 共识建议：外用非甾体抗炎药（NSAIDs）治疗骨关节炎疼痛

2023-03-16 国外风湿免疫科相关专家小组 J Orthop Res 发表于安徽省

非甾体抗炎药骨关节炎疼痛

由于老龄化和肥胖、缺乏运动、关节损伤等危险因素的增加，预计骨关节炎（OA）的患病率将继续上升，疼痛是OA典型表现,外用非甾体抗炎药(NSAIDs)被许多国际指南推荐作为骨关节炎疼痛管理的早期治疗选择，

中文标题：

2023 共识建议：外用非甾体抗炎药（NSAIDs）治疗骨关节炎疼痛

英文标题：

Topical nonsteroidal anti-inflammatory drugs for management of osteoarthritis pain: A consensus recommendation

发布机构：

国外风湿免疫科相关专家小组

发布日期：

2023-03-16

简要介绍：

由于老龄化和肥胖、缺乏运动、关节损伤等危险因素的增加，预计骨关节炎（OA）的患病率将继续上升，疼痛是OA典型表现,外用非甾体抗炎药(NSAIDs)被许多国际指南推荐作为骨关节炎疼痛管理的早期治疗选择，本文主要针对应用外用非甾体抗炎药治疗OA疼痛提供实用指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2023 共识建议：外用非甾体抗炎药（NSAIDs）治疗骨关节炎疼痛.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e03a31c0030e029a, title=2023 共识建议：外用非甾体抗炎药（NSAIDs）治疗骨关节炎疼痛, enTitle=Topical nonsteroidal anti-inflammatory drugs for management of osteoarthritis pain: A consensus recommendation, guiderFrom=J Orthop Res, authorId=0, author=, summary=由于老龄化和肥胖、缺乏运动、关节损伤等危险因素的增加，预计骨关节炎（OA）的患病率将继续上升，疼痛是OA典型表现,外用非甾体抗炎药(NSAIDs)被许多国际指南推荐作为骨关节炎疼痛管理的早期治疗选择，, cover=https://img.medsci.cn/Random/diagnostic-form-in-hospital-conceptual-image-7JAH3GT.jpg, journalId=0, articlesId=null, associationId=893, associationName=国外风湿免疫科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Thu Mar 16 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #333333;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>由于老龄化和肥胖、缺乏运动、关节损伤等危险因素的增加，预计骨关节炎（OA）的患病率将继续上升，疼痛是OA典型表现,外用非甾体抗炎药(NSAIDs)被许多国际指南推荐作为骨关节炎疼痛管理的早期治疗选择，本文主要针对应用外用非甾体抗炎药治疗OA疼痛提供实用指导。</p> </div> </div> </div> <div class="box_info" style="color: #333333;">&nbsp;</div>, tagList=[TagDto(tagId=2061, tagName=非甾体抗炎药), TagDto(tagId=51186, tagName=骨关节炎疼痛)], categoryList=[CategoryDto(categoryId=10, categoryName=骨科, tenant=100), CategoryDto(categoryId=29, categoryName=麻醉疼痛, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=51186, articleKeyword=骨关节炎疼痛, articleKeywordNum=6, guiderKeywordId=51186, guiderKeyword=骨关节炎疼痛, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3234, appHits=155, showAppHits=0, pcHits=588, showPcHits=3077, likes=0, shares=28, comments=6, approvalStatus=1, publishedTime=Tue Apr 04 19:06:00 CST 2023, publishedTimeString=2023-03-16, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Mar 31 23:03:17 CST 2023, updatedBy=2427819, updatedName=梁丽玲, updatedTime=Sat Jan 06 18:35:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=安徽省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 共识建议：外用非甾体抗炎药（NSAIDs）治疗骨关节炎疼痛.pdf)])
2023 共识建议：外用非甾体抗炎药（NSAIDs）治疗骨关节炎疼痛.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2150390, encodeId=ca69215039074, content=全英文。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87f98801479, createdName=ms4000000270342072, createdTime=Sat Jul 29 18:45:26 CST 2023, time=2023-07-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2123822, encodeId=e710212382231, content=下载了学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Wed Apr 05 07:26:24 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123816, encodeId=9d7c21238165e, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230418/2c5df5db186840e7b61bfae9efc81b05/70f6808754774736a252e1f48de0ea66.jpg, createdBy=84788593089, createdName=ms8000000859026375, createdTime=Wed Apr 05 05:34:11 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123912, encodeId=437921239127e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47996472743, createdName=ms6000001129794278, createdTime=Wed Apr 05 15:51:08 CST 2023, time=2023-04-05, status=1, ipAttribution=山东省)]
    2023-07-29 ms4000000270342072 来自广西

    全英文。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2150390, encodeId=ca69215039074, content=全英文。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87f98801479, createdName=ms4000000270342072, createdTime=Sat Jul 29 18:45:26 CST 2023, time=2023-07-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2123822, encodeId=e710212382231, content=下载了学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Wed Apr 05 07:26:24 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123816, encodeId=9d7c21238165e, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230418/2c5df5db186840e7b61bfae9efc81b05/70f6808754774736a252e1f48de0ea66.jpg, createdBy=84788593089, createdName=ms8000000859026375, createdTime=Wed Apr 05 05:34:11 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123912, encodeId=437921239127e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47996472743, createdName=ms6000001129794278, createdTime=Wed Apr 05 15:51:08 CST 2023, time=2023-04-05, status=1, ipAttribution=山东省)]
    2023-04-05 2809 来自山西省

    下载了学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2150390, encodeId=ca69215039074, content=全英文。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87f98801479, createdName=ms4000000270342072, createdTime=Sat Jul 29 18:45:26 CST 2023, time=2023-07-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2123822, encodeId=e710212382231, content=下载了学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Wed Apr 05 07:26:24 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123816, encodeId=9d7c21238165e, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230418/2c5df5db186840e7b61bfae9efc81b05/70f6808754774736a252e1f48de0ea66.jpg, createdBy=84788593089, createdName=ms8000000859026375, createdTime=Wed Apr 05 05:34:11 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123912, encodeId=437921239127e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47996472743, createdName=ms6000001129794278, createdTime=Wed Apr 05 15:51:08 CST 2023, time=2023-04-05, status=1, ipAttribution=山东省)]
    2023-04-05 ms8000000859026375 来自山西省

    很实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2150390, encodeId=ca69215039074, content=全英文。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87f98801479, createdName=ms4000000270342072, createdTime=Sat Jul 29 18:45:26 CST 2023, time=2023-07-29, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2123822, encodeId=e710212382231, content=下载了学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=2809, createdTime=Wed Apr 05 07:26:24 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123816, encodeId=9d7c21238165e, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230418/2c5df5db186840e7b61bfae9efc81b05/70f6808754774736a252e1f48de0ea66.jpg, createdBy=84788593089, createdName=ms8000000859026375, createdTime=Wed Apr 05 05:34:11 CST 2023, time=2023-04-05, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2123912, encodeId=437921239127e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47996472743, createdName=ms6000001129794278, createdTime=Wed Apr 05 15:51:08 CST 2023, time=2023-04-05, status=1, ipAttribution=山东省)]
    2023-04-05 ms6000001129794278 来自山东省

    学习了

    0

相关指南

广东省口服非甾体抗炎药（NSAIDs）临床快速综合评价专家共识

广东省药学会 · 2023-03-08

2023 EAST/OTA实践管理指南：非甾体抗炎药(NSAIDs)治疗骨科创伤后急性疼痛的疗效和安全性

美国东部创伤外科学会(EAST,The Eastern Association for the Surgery of Trauma) · 2023-02-21

2022 中国多学科指南：肌肉骨骼疼痛局部非甾体抗炎药的合理应用（英文）

中国药学会医院药学专业委员会 · 2023-02-15

中国加速康复外科围手术期非甾体抗炎药临床应用专家共识

中华人民共和国国家卫生健康委员会 · 2019-03-30

2018 EAACI意见书：NSAID加重呼吸系统疾病的诊断和管理

欧洲变应性反应与临床免疫学会(EAACI,European Academy of Allergy and Clinical Immunology) · 2018-09-14

拓展阅读

2017 亚太专家组共识建议：应用外用非甾体类抗炎药管理骨关节炎疼痛

随着人口老龄化速度加剧，亚太地区骨关节炎的发生率也在显著增加。本文主要针对亚太地区应用外用非甾体类抗炎药管理骨关节炎疼痛的相关内容提出声明建议。

Arthritis Rheumatol： 针对D系列消退素受体系统治疗骨关节炎疼痛

在2种不同OA动物模型中，D系列消退素旁路的激活具有强大的镇痛作用。

2017 亚太专家组共识建议：应用外用非甾体类抗炎药管理骨关节炎疼痛

亚太地区骨科专家小组（统称） · 2017-12-18

2023 马来西亚共识建议：外用非甾体类抗炎药治疗骨关节炎疼痛

马来西亚骨科研究学会 Orthopaedic Research Society · 2023-03-16